Metabolic & Weight Research Peptides, Read Through Body Composition

The short version

When a person loses weight, the scale reports one number. That number hides two very different things: fat that came off, and lean tissue — mostly muscle — that came off with it. Splitting the two is called body composition, and measuring it takes equipment a bathroom scale does not have.

This review covers four peptides studied in metabolic and weight research: tirzepatide, semaglutide, tesamorelin and MOTS-c. A peptide is a short chain of amino acids, the same building blocks that make up proteins, only far smaller.

The question followed here is narrow. For each compound, what did the published studies actually weigh, scan or estimate? Some of the largest trials on this desk measured body weight and nothing else. One reported lean mass directly, and reported it rising. One has no completed human trial of any kind. Those are three different grades of evidence, and the difference between them matters more than any single percentage.

The frame: one number on the scale, two compartments underneath

Body weight is a single scalar. Body composition partitions that scalar into compartments — at minimum fat mass and fat-free, or lean, mass, and in most reporting conventions bone mineral as a third. The two quantities are not interchangeable, and a trial that reports the first has said nothing at all about the second.

The instruments differ in what they can resolve, and the difference is visible in the units a paper reports. Dual-energy X-ray absorptiometry, usually abbreviated DXA, separates tissue compartments by their differential attenuation of two X-ray energies and reports fat, lean and bone mass in kilograms. Cross-sectional imaging — computed tomography or magnetic resonance — measures one specific fat depot as an area, which is why visceral adipose tissue is conventionally reported in square centimetres at a single anatomical level rather than in kilograms. Bioelectrical impedance analysis, or BIA, infers composition from the resistance of tissue to a small alternating current; it is fast and inexpensive, and it is sensitive to how much water the body is holding. A scale resolves none of this.

That last distinction is not pedantry in this particular literature. Gastrointestinal effects, including the fluid losses that come with vomiting and diarrhoea, are the dominant adverse-effect profile of the incretin agonists on this desk and are concentrated in the period when the dose is being raised ^[11]. Volume depletion is precisely the state in which an impedance estimate drifts. Where a body-composition claim in this field rests on impedance rather than on imaging or DXA, the measurement error and the drug effect point the same way, and the estimate cannot arbitrate between them.

What the trials on this desk actually measured

Sorted by what the primary report put in its results table, the twenty-one sources behind this review fall into three groups.

The first group measured body weight, glycaemia or a clinical event, and did not report body composition. SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes to the maximum tolerated dose of tirzepatide or of semaglutide once weekly for 72 weeks, and reported a least-squares mean weight change of -20.2% against -13.7% ^[1]. SURMOUNT-1 reported mean weight change at week 72 of -15.0%, -19.5% and -20.9% across three tirzepatide dose arms against -3.1% on placebo, in 2,539 adults ^[4]. STEP 1 reported -14.9% against -2.4% on placebo at week 68 with once-weekly semaglutide 2.4 mg ^[10]. SURPASS-2, in 1,879 adults with type 2 diabetes, reported glycated haemoglobin reductions and a weight difference in kilograms ^[5]. SELECT enrolled 17,604 participants and reported major adverse cardiovascular events ^[9]; FLOW enrolled 3,533 and reported kidney-disease events ^[8]. Every one of these is a large, well-powered, genuinely important result. Not one of them is a body-composition result.

The second group measured composition directly, and it belongs entirely to tesamorelin. A meta-analysis of five randomised controlled trials in HIV-associated lipodystrophy reported visceral adipose tissue down by 27.71 cm2, trunk fat down by 1.18 kg, hepatic fat fraction down by 4.28% — and lean body mass up by 1.42 kg ^[12]. An earlier randomised trial in the same population reported a treatment effect of -42 cm2 in visceral fat and a net -2.9% in hepatic lipid over six months ^[14].

The third group is mechanistic and preclinical, and it belongs to MOTS-c. Cell-free work identified casein kinase 2 as a direct binding target, with tissue-specific modulation proposed as the route to muscle glucose uptake and atrophy prevention ^[17]. Exogenous administration improved physical performance in young, middle-aged and old mice ^[20]. The human data are observational biomarker associations rather than interventional outcomes ^[18].

Read against the muscle-sparing question, that ordering is uncomfortable. The compounds with the largest measured weight loss are the ones whose headline trials did not partition it. The only lean-mass increase in this reference list was measured in a different population, for a different indication, by a compound that was not attempting large weight loss. And the compound whose mechanism is the most explicitly muscular has no completed human efficacy trial at all.

What a research peptide is, and what this review is not

Peptides are short amino-acid chains — the same chemistry as proteins, at a fraction of the length. The four on this desk are not a single regulatory category. Tirzepatide and semaglutide are approved prescription medicines with multiple indications between them. Tesamorelin is an approved prescription medicine for one narrow indication, HIV-associated lipodystrophy, and every other use of it is off-label. MOTS-c is not approved for human use anywhere and is supplied only as a laboratory research chemical, with no approved indication, formulation or dosing.

That spread is why a single hub page cannot describe them with one verb. What can be said uniformly is what was measured, in whom, over how long, and with what instrument, and that is the entire remit of this site.

The domain name is borrowed vocabulary from contract manufacturing. This review manufactures nothing, compounds nothing and supplies nothing. It names no vendor, quotes no price, compares no source, links to no shop, and publishes no protocol, schedule or quantity for any person to follow. Where a dose appears on these pages it is a description of what a cited study administered under supervision, reported as a fact about that study. Anything beyond that is a clinical decision, and clinical decisions belong with a qualified prescriber rather than with a literature review.